## Apply for funding for new research in anemia and related areas; up to CHF 200,000 (approx. €130,000) available for each award

## Eligibility

Grant applications are open to established members of academic staff at universities, dialysis centers and research institutes. Applications should focus on the need to improve outcomes and encourage scientific advances relating to the following research areas:

- Anemia of chronic disease
- · Anemia related to congestive heart failure and stroke
- Effects of erythropoietin and erythropoietin like
- substances as protective drugs in various target organsBiology of anemia and outcomes

## Applying for a grant

Two cycles of applications per year for grants of CHF 200,000 (approx. € 130,000) per award

- All applicants must initially provide a **Letter of Intent** with applicant details, title, summary, no more than a 750 word abstract with description of the planned research (objective, background, hypothesis/specific aims, preliminary results (if available), proposed methodology), and estimated funding requirements.
- Letters of Intent are review by an independent Scientific Advisory Board and applicants are short listed for invitation to submit a full application.
- Successful applications will be awarded within six months of the letters of intent deadline.

A total of € 1,870,626 was awarded for the two funding cycles completed in 2005. Seven RoFAR awards were granted in cycle I and eight awards granted in cycle II. Successful projects represented a true cross-section of anemia-related research interests all meet exacting standards for scientific excellence, feasibility and originality set by the organization's independent Scientific Advisory Board.

Deadlines for Letters of Intent are in **June** and **November** of each year.

For more information on award winning projects and cycle and submission dates please visit **www.rofar.org.** 

## About the foundation

RoFAR (The Roche Foundation for Anemia Research) is an independent foundation run by an international Board of Trustees and funded by an unrestricted grant from Roche. It is a non-profit, independent, charitable, funding body that aims to 'encourage innovative research that will open new avenues of exploration in the study of anemia'.

The funding of the Foundation consists of donations from F. Hoffmann-La Roche Ltd.

The Foundation structure involves eight Trustees, from nephrology, oncology, cardiovascular and epidemiology areas and an independently appointed Scientific Advisory Board.

The Foundation is legally independent from F. Hoffmann-La Roche Ltd. and is guided solely by the Board of Trustees according to its charter.

All submissions and details of deadlines for submitting letters of intent can be found on the RoFAR website www.rofar.org

